Catalent extends expansion with $133M deal for Juniper Pharmaceuticals

Money roll
Catalent struck a $133 million deal to buy Juniper Pharmaceuticals. (Pictures of Money/CC BY 2.0)

Somerset, New Jersey-based CDMO Catalent is continuing its investment and expansion campaign, announcing Tuesday that it will buy Juniper Pharmaceuticals for more than $130 million.

Catalent said the deal includes Juniper’s Nottingham, U.K.-based pharma services division, which provides high-end fee-for-service pharmaceutical development and clinical trials manufacturing.

“Juniper’s proven solutions and capabilities will further support Catalent’s strategic goal to be the most comprehensive partner for pharmaceutical innovators,” Jonathan Arnold, president of Catalent Oral Drug Delivery, said in a statement.

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

Catalent is paying $11.50 per share for the Boston-based development specialist. Juniper shares closed Monday at $8.70 per share.

Juniper also has contract with Merck KGaA to supply Crinone progesterone gel outside of the United States, an agreement that Catalent will continue. The deal is expected to close this quarter.

RELATED: Catalent doubles down on biologics with $950M deal for Cook Pharmica

This deal follows Catalent’s decision last fall to pay $950 million to buy Cook Pharmica. In that deal, Catalent got Cook’s 875,000-square-foot development and manufacturing facility in in Bloomington, Indiana, along with 750 new employees.

Catalent currently has approximately 11,000 employees, more than 30 facilities across five continents, and in fiscal 2017 generated over $2 billion in annual revenue.

Suggested Articles

Boehringer Ingelheim intends to make a significant investment in its three manufacturing sites in Mexico in the next three years.

Dendreon has signaled faith in its struggling prostate drug Provenge by signing a 10-year lease extension for its California manufacturing facility.

Daiichi Sankyo says it still unable to fulfill a government mandate to be able to produce enough H5N1 flu vaccine to fight an epidemic in Japan.